Therapeutic decisions inmultiple sclerosis moving beyond efficacy

JAMA Neurology

Volumn 70, Issue 10, 2013, Pages 1315-1324

  Brück, Wolfgang ^a   Gold, Ralf ^b   Lund, Brett T ^c   Oreja Guevara, Celia ^d   Prat, Alexandre ^e   Spencer, Collin M ^j   Steinman, Lawrence ^f   Tintoré, Mar ^g   Vollmer, Timothy L ^h   Weber, Martin S ^a   Weiner, Leslie P ^c   Ziemssen, Tjalf ⁱ   Zamvil, Scott S ^j,k  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e UNIVERSITY OF MONTREAL   (Canada)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; DACLIZUMAB; EFALIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; LAQUINIMOD; LEFLUNOMIDE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; IMMUNOLOGIC FACTOR;

ALOPECIA; BLOOD PRESSURE; BRADYCARDIA; CELL DIVISION; CELL FUNCTION; CELL MIGRATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; FLUSHING; GOODPASTURE SYNDROME; GRAVES DISEASE; HEART INFARCTION; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOCOMPETENT CELL; INFECTION; INFLAMMATION; LIVER TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; MORBIDITY; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT CARE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; UPPER ABDOMINAL PAIN; DRUG EFFECT; HUMAN EXPERIMENT; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM;

HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 84885730321     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.3510     Document Type: Review

References (109)

1. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520-532.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502- 1517.
3. Brück W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci. 2003;24(suppl 5):S265-S267. (Pubitemid 37493197)
4. Prod'homme T, Zamvil SS. Bench to bedside: tempering antigen-presenting cells in multiple sclerosis. Nat Med. 2008;14(6):614-615.
5. Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007;13(8):935-943. (Pubitemid 47222047)
6. Kieseier BC, Stüve O. A critical appraisal of treatment decisions in multiple sclerosis: old vs new. Nat Rev Neurol. 2011;7(5):255-262.
7. Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172(21):1680- 1681.
8. Rawlins MD, Thomson JW. Mechanisms of adverse drug reactions. In: Davies DM, ed. Textbook of Adverse Drug Reactions. 4th ed. New York, NY: Oxford University Press; 1991.
9. Wingerchuk DM. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management. Expert Rev Neurother. 2006;6(3):333-346.
10. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9): 899-910.
11. Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
12. Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am J Gastroenterol. 2003;98(11):2372-2382. (Pubitemid 37448744)
13. Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71(17):1350-1354.
14. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5):743-747. (Pubitemid 43673151)
15. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375-381. (Pubitemid 41132342)
16. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4):369-374. (Pubitemid 41132341)
17. Global natalizumab (TYSABRI) safety update. Weston, MA: Biogen Idec; February 5, 2013.
18. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
19. Monaco MC, Major EO. The link between VLA-4 and JC virus reactivation. Expert Rev Clin Immunol. 2012;8(1):63-72.
20. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303.
21. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35-47.
22. Tysabri [package insert]. Cambridge, MA: Biogen Idec; 2012.
23. Lenhard T, Biller A, Mueller W, Metz I, Schönberger J, Wildemann B. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology. 2010;75(9):831-833.
24. Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J Clin Immunol. 2011;31(4):623-631.
25. Rigau V, Mania A, Béfort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology. 2012;79(22):2214-2216.
26. Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
27. Kappos L, Radue EW, O'Connor P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
28. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759-777.
29. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther. 2007;323(2):469-475.
30. Ratchford JN, Costello K, Reich DS, Calabresi PA. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology. 2012;79(19):2002-2004.
31. MS study evaluating safety and efficacy of two doses of fingolimod versus copaxone [NCT01633112]. http://clinicaltrials.gov/ct2/show/NCT01633112. Accessed March 11, 2013.
32. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2012.
33. Johnson TA, Shames I, Keezer M, et al. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients. Clin Immunol. 2010;137(1):15-20.
34. Brinkmann V, Baumruker T. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol. 2006;6(3):244-250. (Pubitemid 44274746)
35. Olsson T, Boster A, Fernandez O, et al. Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trial. Mult Scler. 2012;18(4)(suppl):49-50.
36. Stuve O, Selmaj K, Li D, et al. BAF312, a selective sphingosine-1- phosphate receptor modulator improves MRI and clinical outcomes in relapsing-remitting multiple sclerosis (RRMS) (S30.001). Neurology. 2012;78(meeting abstracts 1):S30.001. doi:10.1212/WNL.78.1-MeetingAbstracts.S30. 001.
37. Vollmer T, Selmaj K, Bar-Or A, Zipp FA. Double-blind, placebo-controlled, phase 2, 26-week DreaMS trial of a selective S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis. Neurology. 2012;79(11):e87-e91.
38. Coles AJ, Compston DA, Selmaj KW, et al; CAMMS223 Trial Investigators. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.
39. Cohen JA, Coles AJ, Arnold DL, et al; CARE-MS I Investigators. Alemtuzumab vs interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828.
40. Coles AJ, Twyman CL, Arnold DL, et al; CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839.
41. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691-1695. (Pubitemid 29533060)
42. Coles A, Brinar V, Arnold D, et al. Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I (CARE-MS I): a phase 3 study in relapsing-remitting treatment-naive patients (S01.006). Neurology. 2012;78(meeting abstracts 1):S01.006. doi:10.1212/WNL.78.1- MeetingAbstracts.S01.006.
43. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573-579.
44. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052-2061.
45. Hauser SL, Waubant E, Arnold DL, et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688. (Pubitemid 351240747)
46. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779-1787.
47. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581. (Pubitemid 38758544)
48. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67(4):452-461.
49. Weber MS, Prod'homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010;68(3):369-383.
50. F. Hoffmann-La Roche Ltd. Roche and Biogen Idec decide to suspend Ocrelizumab treatment: rheumatoid arthritis development programme on hold. http://www.roche.com/media/media-releases/med-cor-2010-03-08.htm Accessed March 11, 2013.
51. Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathyin autoimmune diseases. Joint Bone Spine. 2012;79(4):351-355.
52. Rituxan [package insert]. South San Francisco, CA: Genentech; 2012.
53. Fox RJ, Miller DH, Phillips JT, et al; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097.
54. Gold R, Kappos L, Arnold DL, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
55. Litjens NH, Burggraaf J, van Strijen E, et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004;58(4):429-432. (Pubitemid 39312467)
56. Ghoreschi K, Brück J, Kellerer C, et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med. 2011;208(11):2291-2303.
57. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(pt 3):678-692.
58. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284(20):13291-13295.
59. Rostami Yazdi M, Mrowietz U. Fumaric acid esters. Clin Dermatol. 2008;26(5):522-526.
60. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol. 2009;129(1):231-234.
61. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol. 2011;85(4):241-272.
62. Frycák P, Zdráhal Z, Ulrichová J, Wiegrebe W, Lemr K. Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides. J Mass Spectrom. 2005;40(10):1309-1318. (Pubitemid 41552471)
63. Schmidt TJ, Ak M, Mrowietz U. Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine: preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem. 2007;15(1):333-342. (Pubitemid 44738571)
64. Albrecht P, Bouchachia I, Goebels N, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163.
65. Litjens NH, Rademaker M, Ravensbergen B, Thio HB, van Dissel JT, Nibbering PH. Effects of monomethylfumarate on dendritic cell differentiation. Br J Dermatol. 2006;154(2):211-217. (Pubitemid 43382688)
66. Lehmann JC, Listopad JJ, Rentzsch CU, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007;127(4):835-845. (Pubitemid 46434667)
67. Tecfidera [package insert]. Cambridge, MA: Biogen Idec; 2013.
68. Phillips JT, Fox RJ, Selmaj K, et al. Long-term safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: interim results from ENDORSE. Mult Scler. 2012;18(4)(suppl):517-518.
69. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med. 2013;368(17):1659-1661.
70. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657-1658.
71. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368(17):1658-1659.
72. Litjens NH, van Strijen E, van Gulpen C, et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 2004;4:22.
73. Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA; American Academy of Clinical Toxicology Ad Hoc Committee on the Treatment Guidelines for Methanol Poisoning. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40(4):415-446. (Pubitemid 34976720)
74. Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008;3(1):208-225.
75. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol. 2004;17(1):3-16. (Pubitemid 38134055)
76. Hanson J, Gille A, Offermanns S. Role of HCA (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol Ther. 2012;136(1):1-7.
77. Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, Meyer CJ. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney. J Am Soc Nephrol. 2012;23(10):1663-1673.
78. Comi G, Jeffery D, Kappos L, et al; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-1009.
79. Vollmer TL, Soelberg Sorensen P, Arnold DL; BRAVO Study Group. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. Mult Scler. 2011;17(10)(suppl):S507- S508.
80. Noseworthy JH, Wolinsky JS, Lublin FD, et al; North American Linomide Investigators. Linomide in relapsing and secondary progressive MS, part I: trial design and clinical results. Neurology. 2000;54(9):1726-1733. (Pubitemid 30428397)
81. Jönsson S, Andersson G, Fex T, et al. Synthesis and biological evaluation of new 1, 2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem. 2004;47(8):2075-2088. (Pubitemid 38453923)
82. Schulze-Topphoff U, Shetty A, Varrin-Doyer M, et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One. 2012;7(3):e33797.
83. Mishra MK, Wang J, Silva C, Mack M, Yong VW. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol. 2012;181(2):642-651.
84. Brück W, Pförtner R, Pham T, et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012;124(3):411-424.
85. Ruffini F, Rossi S, Bergamaschi A, et al. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis [published online December 11, 2012]. Mult Scler. doi:10.1177/1352458512469698.
86. Thöne J, Ellrichmann G, Seubert S, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol. 2012;180(1):267-274.
87. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. 2007;69(8):785-789. (Pubitemid 47300936)
88. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA. 2004;101(23):8705-8708. (Pubitemid 38745835)
89. Wynn D, Kaufman M, Montalban X, et al; CHOICE Investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010;9(4):381-390.
90. Gold R, Giovannoni G, Selmaj K, et al; SELECT Study Investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167-2175.
91. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006;103(15):5941-5946.
92. Hartung HP, Gonsette R, König N, et al; Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-2025. (Pubitemid 36026580)
93. Malonne H, Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs. 1997;8(9):811-822. (Pubitemid 27487794)
94. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463-1470.
95. O'Connor P, Wolinsky JS, Confavreux C, et al; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
96. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93(3):198-208.
97. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans: disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem. 1995;270(50): 29682-29689.
98. Fukushima R, Kanamori S, Hirashiba M, et al. Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine. Toxicol Sci. 2009;108(2):419-426.
99. Aubagio [package insert]. Cambridge, MA: Genzyme; 2012.
100. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet. 2002;41(6):421-430. (Pubitemid 34753679)
101. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009;32(12):1123-1134.
102. US Food and Drug Administration. FDA Drug Safety Communication: new boxed warning for severe liver injury with arthritis drug Arava (leflunomide). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor- PatientsandProviders/ucm218679.htm. Accessed March 11, 2013.
103. Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol. 2008;64(9):871-876.
104. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol. 2012;142(1):49-56.
105. Stüve O, Youssef S, Weber MS, et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest. 2006;116(4):1037-1044.
106. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390-1395.
107. Sorensen PS, Lycke J, Erälinna JP, et al; SIMCOMBIN Study Investigators. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691-701.
108. Zamvil SS, Steinman L. Combining statins with interferon β in multiple sclerosis: think twice, it might not be all right. Lancet Neurol. 2011;10(8):672-673.
109. Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009;132(pt 9):2517-2530.